News

UroGen's ZUSDURI revenue doubled to $29.2M in Q1 2026 following permanent J-code approval, signaling reimbursement as the primary adoption...

TG Therapeutics raises BRIUMVI revenue guidance to $885–$900M, driven by record Q1 patient starts and aggressive commercial investment in...

BioCryst licenses navenibart European rights to Neopharmed Gentili for $70M upfront, securing funding before regulatory approval.

Roche acquires PathAI in $1.05 billion AI diagnostics deal to strengthen its companion diagnostic capabilities and secure proprietary biomarker...

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion, gaining three FDA-approved drugs and U.S. commercial infrastructure in a...

INmune Bio expands CORDStrom Platform across four disease indications including rare skin disease, solid tumors, and autoimmune conditions with...

Supernus Reports 39% Q1 Revenue Growth Despite Operating Loss, driven by Qelbree and collaboration revenue from ZURZUVAE.

Gyre Therapeutics completes $300M acquisition of Cullgen, combining China-based TPD discovery with U.S.-listed equity and late-stage fibrosis programs.

Rhythm Pharmaceuticals reports Q1 IMCIVREE sales decline in U.S. market amid specialty pharmacy dynamics and insurance coverage transitions.

Gyre Therapeutics completes $300M acquisition of Cullgen to combine protein degrader platform with fibrosis franchise generating China revenue.